Skip to main content

Advertisement

Table 1 Demographic characteristics at baseline

From: Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study

  Placebo IFN β-1a 22 μg SC tiw IFN β-1a 44 μg SC tiw
Number of active T2 lesions at 6 months All (n = 187) Number of active T2 lesions at 6 months All (n = 189) Number of active T2 lesions at 6 months All (n = 184)
0 (n = 39) ≥4 (n = 64) 0 (n = 85) ≥4 (n = 28) 0 (n = 95) ≥4 (n = 24)
Age, years, mean (SD) 36.4 (7.3) 33.4 (7.8) 34.7 (7.5) 35.6 (6.5) 30.2 (7.3) 34.8 (7.0) 35.5 (8.0) 33.0 (6.7) 35.2 (7.9)
Sex, female, n (%) 31 (79) 47 (73) 141 (75) 53 (62) 21 (75) 126 (67) 63 (66) 14 (58) 122 (66)
Race, white, n (%) 38 (97) 63 (98) 184 (98) 84 (99) 28 (100) 188 (99) 94 (99) 24 (100) 182 (99)
Time since MS onset, years, mean (SD) 6.6 (5.4) 5.3 (4.3) 6.1 (4.8) 7.9 (6.45) 5.4 (4.3) 7.7 (6.1) 7.1 (5.6) 7.4 (6.9) 7.8 (6.3)
Number of relapses in past 2 years, mean (SD) 2.7 (0.8) 3.3 (1.4) 3.0 (1.3) 2.9 (1.0) 3.2 (1.2) 3.0 (1.1) 2.9 (1.0) 3.5 (1.6) 3.0 (1.1)
EDSS score, median 2.0 2.5 2.5 2.5 2.0 2.5 2.5 3.0 2.5
  1. EDSS Expanded Disability Status Scale, IFN β-1a interferon beta-1a, SC subcutaneously, SD standard deviation, tiw three times weekly